The Medication Management: Investigational Study Drug Policy is now in place, effective June 4, 2024. The policy was developed to define the responsibilities of the University’s Investigational Drug Service (IDS), as it pertains to the management of prospective therapeutic interventional research that is conducted or supported by employees of the University. Among other IDS-specific procedures, the policy specifies that:
- All human subject research involving drugs as the test object of a study will undergo ancillary review by IDS; and
- Study teams are expected to delegate drug management responsibilities to IDS.
Study teams wishing to use methods other than IDS to manage investigational drugs will need to submit an exemption request or review.
The policy and exemption request process will be reviewed during the September 12th UR-HRPP Educational Forum (with the recording available for later viewing via OHSP’s UR-HRPP Educational Materials).
Register for the 9/12 UR-HRPP Educational Forum
For questions regarding UR-HRPP Educational Forums, contact Kelly Unsworth.